VANCOUVER, BC – Virogin Biotech today announced that it will present results from preclinical studies evaluating the effects of pre-existing HSV-1 immunity on anti-cancer efficacy of VG161 – the company’s lead product candidate, in tumor models. The results will be available as a poster presentation during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, taking place from April 10-15, 2021.

Details on the poster and abstract are below. The poster will be made available on the AACR Conference website on April 10, 2021

Title: Pre-existing HSV-1 Immunity enhances anti-cancer efficacy of a novel immune stimulating oncolytic virus – VG161
Session Type: E-Poster Session
Session Title: Vaccines
Abstract Number: 1913

About VG161
VG161 is an attenuated herpes simplex virus type 1 (HSV-1), built on Virogin’s Synerlytic™ Platform, which expresses a unique combination of cytokines that act synergistically to boost the innate and adaptive immune responses in the tumor microenvironment. VG161 has a deletion of the ICP34.5 gene to prevent neurovirulence

About Virogin Biotech
Virogin Biotech is a clinical stage oncolytic virus company that is developing next-generation oncolytic virotherapies to enhance systemic antitumor immunity. Led by a team with over 25 years of experience in fundamental research, translational and clinical development of immunotherapy & oncolytic virotherapy, Virogin is determined to be a global, best-in-class oncolytic virus company that creates impactful therapies for patients of the highest medical need.